Resmetirom

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 379 publications

Estimation of Rezdiffra (MGL-3196) by Validated RP-HPLC Approach in Bulk Material and Pharmaceutical Formulation.

Estimation of Rezdiffra (MGL-3196) by Validated RP-HPLC Approach in Bulk Material and Pharmaceutical Formulation.

Journal: Drug development and industrial pharmacy

Published: April 07, 2026

Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver Disease.

Updated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver Disease.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: February 26, 2026

MASH and liver fibrosis: Clinical trials to watch.

MASH and liver fibrosis: Clinical trials to watch.

Journal: Med (New York, N.Y.)

Published: February 25, 2026

Therapeutic targets for metabolic dysfunction-associated steatohepatitis: a personalized approach to disease management.

Therapeutic targets for metabolic dysfunction-associated steatohepatitis: a personalized approach to disease management.

Journal: Nature reviews. Gastroenterology & hepatology

Published: February 24, 2026

Therapeutic potential of TMSC-Exo for non-alcoholic fatty liver disease using the liver-on-a-chip model.

Therapeutic potential of TMSC-Exo for non-alcoholic fatty liver disease using the liver-on-a-chip model.

Journal: Journal of translational internal medicine

Published: February 23, 2026

Levothyroxine for metabolic dysfunction-associated steatohepatitis: it is the prime time for randomized controlled trials.

Levothyroxine for metabolic dysfunction-associated steatohepatitis: it is the prime time for randomized controlled trials.

Journal: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

Published: February 16, 2026

Real-World Safety and Monitoring Practices in Patients Receiving Resmetirom for MASH: A Single Center Retrospective Review.

Real-World Safety and Monitoring Practices in Patients Receiving Resmetirom for MASH: A Single Center Retrospective Review.

Journal: Gastroenterology & hepatology

Published: February 09, 2026

Improvement in Health-Related Quality of Life After Treatment With Resmetirom in Cirrhotic and Noncirrhotic Patients With MASLD: Data From MAESTRO-NAFLD-1.

Improvement in Health-Related Quality of Life After Treatment With Resmetirom in Cirrhotic and Noncirrhotic Patients With MASLD: Data From MAESTRO-NAFLD-1.

Journal: Gastroenterology & hepatology

Published: February 09, 2026

Changes in Health-Related Quality of Life, Cognitive Dysfunction, and Worry Domains in Patients With MASLD and MASH Treated With Resmetirom.

Changes in Health-Related Quality of Life, Cognitive Dysfunction, and Worry Domains in Patients With MASLD and MASH Treated With Resmetirom.

Journal: Gastroenterology & hepatology

Published: February 09, 2026

Two-Year Time Course of Biomarker and Imaging Responses in Patients With Well-Compensated MASH Cirrhosis Treated With Resmetirom.

Two-Year Time Course of Biomarker and Imaging Responses in Patients With Well-Compensated MASH Cirrhosis Treated With Resmetirom.

Journal: Gastroenterology & hepatology

Published: February 09, 2026

Distinct Lipid and Liver Enzyme Trajectories in Diabetic vs Nondiabetic MASLD/MASH Patients Treated With Resmetirom: A Multicenter Propensity-Matched Analysis.

Distinct Lipid and Liver Enzyme Trajectories in Diabetic vs Nondiabetic MASLD/MASH Patients Treated With Resmetirom: A Multicenter Propensity-Matched Analysis.

Journal: Gastroenterology & hepatology

Published: February 09, 2026

Comparison of MAESTRO-NASH and ESSENCE: Effects of Resmetirom and Semaglutide Relative to Placebo on Primary and Secondary Liver Biopsy Endpoints Using Aligned Endpoints and Statistical Methods.

Comparison of MAESTRO-NASH and ESSENCE: Effects of Resmetirom and Semaglutide Relative to Placebo on Primary and Secondary Liver Biopsy Endpoints Using Aligned Endpoints and Statistical Methods.

Journal: Gastroenterology & hepatology

Published: February 09, 2026

Showing 1-12 of 379

Last Updated: 04/28/2026